Alto Neuroscience, Inc. ANRO

Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with basic loss per share from continuing operations of US$0.65 and US$1.34, respectively. Despite these larger losses, analysts have maintained a strongly positive stance on Alto Neuroscience, highlighting the progress of its clinical-stage pipeline targeting bipolar depression and major depressive...

Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last 12 months, Alto Neuroscience has returned about 9.2x an initial investment, which raises the hurdle for any new buyers who are sensitive to valuation. The expanded development of ALTO-207 and the recent funding that is expected to support operations for several years can help underpin growth...